首页> 外国专利> RECURRENT FUSION GENES IDENTIFIED IN HIGH-GRADE SEROUS OVARIAN CARCINOMA

RECURRENT FUSION GENES IDENTIFIED IN HIGH-GRADE SEROUS OVARIAN CARCINOMA

机译：高级别浆液性卵巢癌中的轮回融合基因

页面导航

摘要
著录项
相似文献

摘要

Embodiments of the disclosure include methods and compositions associated with CDKN2D-WDFY2 chimeric RNA, the fusion gene that produces the chimeric RNA, and polypeptides produced from the chimeric RNA. In particular embodiments, the chimeric RNA is useful for methods of treatment, diagnosis, and/or prognosis as they relate to ovarian cancer, or therapy therefor, including at least high-grade serous carcinoma.

机译：本公开的实施方案包括与 CDKN2D-WDFY2 嵌合RNA，产生该嵌合RNA的融合基因以及从该嵌合RNA产生的多肽相关的方法和组合物。在特定的实施方案中，嵌合RNA可用于治疗，诊断和/或预后的方法，因为它们涉及卵巢癌或其治疗，包括至少高度恶性浆液性癌。 展开▼

著录项

公开/公告号WO2015120482A2

专利类型

公开/公告日2015-08-13

原文格式PDF

申请/专利权人 BAYLOR COLLEGE OF MEDICINE;
展开▼

申请/专利号WO2015US15284

发明设计人 YEN LAISING;KANNAN KALPANA;
展开▼

申请日2015-02-10

分类号C12Q1/68;G01N33/574;

国家 WO

入库时间 2022-08-21 15:04:50

相似文献

专利

外文文献

中文文献

1. miRNA用于高级别浆液性卵巢癌治疗护理的预测和预后用途 [P] . 中国专利： CN112368399A . 2021-02-12

2. 一组用于预测高级别浆液性卵巢癌预后的标志物及其应用 [P] . 中国专利： CN113774135A . 2021-12-10

3. RECURRENT FUSION GENES IDENTIFIED IN HIGH-GRADE SEROUS OVARIAN CARCINOMA [P] . 世界知识产权组织专利： WO2015120482A3 . 2015-10-15

机译：高级别浆液性卵巢癌中的轮回融合基因

4. RECURRENT FUSION GENES IDENTIFIED IN HIGH -GRADE SEROUS OVARIAN CARCINOMA [P] . 美国专利： US2016340743A1 . 2016-11-24

机译：高级别浆液性卵巢癌中的轮回融合基因

5. HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) [P] . EP3931570A1 . 2022-01-05

机译：高级浆液卵巢癌（HGSOC）

1. Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer [J] . Yan Sun, Da Yang, Wei Zhang, 癌症（英文版） . 2015,第001期

2. Morphological and molecular basis of ovarian serous carcinoma [J] . Daniel G Rosen, Zhihong Zhang, Weiwei Shan, 生物医学研究杂志（英文版） . 2010,第004期

3. Morphological and molecular basis of ovarian serous carcinoma [J] . Daniel G Rosen, Zhihong Zhang, Weiwei Shan, 生物医学研究杂志：英文版 . 2010,第004期

4. CDKN2D-WDFY2 Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma [J] . Kalpana Kannan, Cristian Coarfa, Kimal Rajapakshe, PLoS Genetics . 2014,第3期

5. CDKN2D-WDFY2 Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma [J] . Kalpana Kannan, Cristian Coarfa, Kimal Rajapakshe, PLoS Genetics . 2014,第3期

6. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis [J] . Inigo Espinosa, Lluis Catasus, Belén Canet, Modern Pathology . 2011,第6期

7. Global proteomic analysis of ovarian high-grade serous carcinomas using SWATH-MS for targeted verification of proteome changes associated with genomic alterations [C] . Stefani N. Thomas, Jing Chen, Paul Aiyetan, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

8. Inhibitory Functions of SUSD2 in the Progression of High-Grade Serous Ovarian Carcinoma. [D] . Sheets, Jordan N. 2017

9. PNAS Plus: Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma [O] . Kalpana Kannan, Cristian Coarfa, Pei-Wen Chao, 2015

10. Recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma [O] . Kalpana Kannan, Cristian Coarfa, Pei-Wen Chao, 2015

11. Pathogenesis of Ovarian Serous Carcinoma as the Basis for Immunologic Directed Diagnosis and Treatment. Project 1 - Molecular Characterization of Ovarian Serous Tumors Developing Along Different Pathways [R] . Kurman, R. J. , Shih, I. 2003

1. Clinical Significance of Serum Galectin-1 and Its Tissue Immunohistochemical Expression in Serous Ovarian Carcinoma Patients [J] . Mai Mohamed Abdelwahab ,Huda Fathy Ebian ,Taiseer Refat Ibrahim . 妇产科期刊（英文） . 2019,第7期

2. Uterine papillary serous carcinoma: Its clinical and fundamental studyUterine papillary serous carcinoma: Its clinical and fundamental study [J] . Geng Yi Sun Jianheng Jiang Sen ( Department of Gynecological Oncology Cancer Hospital Chinese Academy of Medical Sciences 100021 ,Department of Obstetrics and Gynecology The QIIU Hospital of Shandong University 250012) . 现代妇产科进展 . 2000,第6期

3. miR-145在浆液性卵巢癌发生发展中的作用和机制研究 [C] . . 山东省抗癌协会第五次会员代表大会暨山东省第四届肿瘤学术大会 . 2015

4. 基于整合组学探讨细胞周期相关基因在高级别浆液性卵巢癌发生及发展中的作用 [A] . 周潇妮 . 2020